Terms: = Lymphoma AND PCM1, Q15154, PTC4, ENSG00000078674, 5108 AND Treatment
9 results:
1. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.
Zhang L; Shah B; Zhang Y; Tashkandi H; Xiao W; Fernandez-Pol S; Vergara-Lluri M; Hussaini M; Song J; Lancet J; Moscinski L; Yun S; Lu CM; Medeiros LJ; Tang G
Hum Pathol; 2023 Jun; 136():1-15. PubMed ID: 36958463
[TBL] [Abstract] [Full Text] [Related]
2. pcm1::JAK2 fusion associates with an atypical form of mycosis fungoides.
Rodriguez-Sevilla JJ; Salido M; Rodriguez-Rivera M; Sanchez-Gonzalez B; Gallardo F; Pujol RM; Colomo L
Virchows Arch; 2022 Dec; 481(6):967-973. PubMed ID: 35786767
[TBL] [Abstract] [Full Text] [Related]
3. pcm1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.
Kaplan HG; Jin R; Bifulco CB; Scanlan JM; Corwin DR
Oncologist; 2022 Aug; 27(8):e661-e670. PubMed ID: 35472244
[TBL] [Abstract] [Full Text] [Related]
4. A neoplasm with FIP1L1-PDGFRA fusion presenting as pediatric T-cell lymphoblastic leukemia/lymphoma without eosinophilia.
Oberley MJ; Denton C; Ji J; Hiemenz M; Bhojwani D; Ostrow D; Wu S; Gaynon P; Raca G
Cancer Genet; 2017 Oct; 216-217():91-99. PubMed ID: 29025601
[TBL] [Abstract] [Full Text] [Related]
5. t(8;9)(p22;p24)/pcm1-JAK2 activates SOCS2 and SOCS3 via STAT5.
Ehrentraut S; Nagel S; Scherr ME; Schneider B; Quentmeier H; Geffers R; Kaufmann M; Meyer C; Prochorec-Sobieszek M; Ketterling RP; Knudson RA; Feldman AL; Kadin ME; Drexler HG; MacLeod RA
PLoS One; 2013; 8(1):e53767. PubMed ID: 23372669
[TBL] [Abstract] [Full Text] [Related]
6. Hematologic adverse events associated with temozolomide.
Villano JL; Letarte N; Yu JM; Abdur S; Bressler LR
Cancer Chemother Pharmacol; 2012 Jan; 69(1):107-13. PubMed ID: 21614470
[TBL] [Abstract] [Full Text] [Related]
7. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
[TBL] [Abstract] [Full Text] [Related]
8. pcm1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.
Hoeller S; Walz C; Reiter A; Dirnhofer S; Tzankov A
Expert Opin Ther Targets; 2011 Jan; 15(1):53-62. PubMed ID: 21091042
[TBL] [Abstract] [Full Text] [Related]
9. [The expression of CD19 in 210 cases of childhood acute leukemia and its significance].
Chen YH; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Qian BQ; Xu WQ; Ning BT
Zhonghua Er Ke Za Zhi; 2004 Mar; 42(3):188-91. PubMed ID: 15144712
[TBL] [Abstract] [Full Text] [Related]
